Patent intelligence · US
US 10980780
Methods and compositions of anti-inflammatory drug and dicer activator for treatment of neuronal diseases
Methods and compositions of anti-inflammatory drug and dicer activator for treatment of neuronal diseases
Patent details — US 10980780
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 20, 2021
- Expiration
- Apr 15, 2041
- Applicant
- NEUROSENSE THERAPEUTICS LTD.
- Claims
- 19
- CPC classes
- A61K, A61K31/415, A61K31/416, A61K31/496
Quick answer
US 10980780 (Methods and compositions of anti-inflammatory drug and dicer activator for treatment of neuronal diseases) is held by NEUROSENSE THERAPEUTICS LTD.. Status: granted. Granted Apr 20, 2021. Expires Apr 15, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- NEUROSENSE THERAPEUTICS LTD.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/415, A61K31/416, A61K31/496, A61P, A61P25/00
More from NEUROSENSE THERAPEUTICS LTD.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 10980780?
US 10980780 (Methods and compositions of anti-inflammatory drug and dicer activator for treatment of neuronal diseases) is held by NEUROSENSE THERAPEUTICS LTD.. Status: granted. Granted Apr 20, 2021. Expires Apr 15, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10980780?
NEUROSENSE THERAPEUTICS LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 10980780 expire?
Our index shows an expiration date of Apr 15, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.